London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

GlaxoSmithKline Pharma is shifting focus to specialty treatments and preventive healthcare, emphasizing adult vaccines and ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

Responding to growing pressure, ViiV Healthcare announced steps to widen access to its HIV prevention medicine in low- and ...

Faced with a moribund share sale outlook and emboldened by their growing recognition on the global stage, some Chinese ...

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

Inhalers used to treat symptoms of respiratory disease can be potent sources of greenhouse gases. Drugmakers are planning to ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...